The global 3D cell culture and 3D bioprinting market was valued at $ xx billion in 2020

    Home / Business Markets / The global 3D cell culture and 3D bioprinting market was valued at $ xx billion in 2020

The global 3D cell culture and 3D bioprinting market was valued at $ xx billion in 2020

0

ReportLinker

ReportLinker

Predictions by technology (scaffold-based, scaffold-free, microfluidics-based, magnetic levitation, 3D bioprinting, others), by application (cancer and stem cell research, drug discovery and toxicology testing, tissue engineering and regenerative medicine), by user end (pharmaceutical and biotech companies, academic institutes, research laboratories, others) E Analysis of leading regional and national market MORE Analysis of leading companies AND COVID-19 recovery scenarios

New York, March 18, 2022 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the “3D Cell Culture and 3D Bioprinting Market Report 2022-2032” – https://www.reportlinker.com/p06245875/?utm_source = GNW

The global 3D Cell Culture & 3D Bioprinting market was valued at $ xx billion in 2020 and is expected to grow at a CAGR of xx% over the forecast period 2022-2032. The growing demand for new drug development, 3D bioprinting for organ transplantation, growing stem cell research is one of the main drivers of market growth. The increasing use of the 3D cell culture model in cancer research, 3D bioprinting for drug discovery and development in pharmaceuticals, 3D bioprinting for emerging animal-free meat economies are some of the main drivers driving the market globalization of 3D cell culture and 3D bioprinting.

How has COVID-19 had a significant negative impact on the 3D cell culture and 3D bioprinting market?

The COVID-19 pandemic has a significant negative impact on 3D cell culture and the 3D bioprinting market globally. The COVID-19 outbreak in 2020 led to international border controls, nationwide lockdowns, restrictions and limitations on pharmaceutical production. This pandemic has hampered the production and distribution of 3D cell cultures and 3D bioprinting technologies.

COVID-19 would undoubtedly have an effect on chronic and infectious disease patients and their care for the foreseeable future. Building support networks for doctors and patients will help break down walls and provide patients with appropriate access to potentially life-saving services.

This report includes data analytics and valuable insights into how COVID-19 will affect your industry. Access this report today.

How will this relationship benefit you?

Visiongain’s 380+ page report provides 356 tables and 352 charts / graphs. Our new study is suitable for anyone requiring in-depth business analysis for the global 3D Cell Culture and 3D Bioprinting market, along with detailed market segment analyzes. Our new study will help you evaluate the global global and regional market for 3D Cell Culture and 3D Bioprinting. Get financial analysis of the general market and different segments, including technology, application and end user, and gain higher market shares. We believe that great opportunities remain in this rapidly growing market for tissue engineering and regenerative medicine. Find out how to use existing and future opportunities in this market to gain revenue benefits in the near future. In addition, the report would help you improve your strategic decision making, allowing you to frame growth strategies, strengthen the analysis of other market players and maximize the productivity of the company.

What are the current market drivers?

Development on the rise for the development of new drugs

Rising demand for drug development is expected to spur demand for 3D cell cultures and 3D bioprinting. According to the WHO, the prevalence of chronic disease cases is projected to increase by 57%, with higher disease cases in low- and middle-income nations. Additionally, the outbreak of present and past pandemics such as COVID19, SARS, Ebola, MERS and H1N1 have added to the surge in drug development and vaccination.

Stem cell research on the rise and 3D bioprinting for organ transplantation
3D bioprinting for organ transplantation, growing stem cell research and the use of the 3D cell culture model in cancer research are further driving market adoption. Pharmaceutical companies such as Corning Inc., Thermo Fisher Scientific Inc., Merck Group and Lonza Group are constantly investing in 3D cell culture and 3D bioprinting to enhance market growth. Additionally, the growing number of chronic disease patients coupled with growing health awareness is expected to increase the demand for 3D cell cultures and 3D bioprinting.

Where are the market opportunities?

Development of biocompatible and printable biomaterials

The growing daily demand in the medical field for bio-alternatives that may be able to perform the living activities of the body’s organs has sparked the interest of researchers in the design of new biomaterials. Hence, market leaders are moving from conventional techniques to innovative and improved techniques, thus developing biocompatible and printable biomaterials.
3D bioprinting for meat without animals

Organoids developed from pluripotent stem cells or adult stem cells are three-dimensional cell cultures that possess some key characteristics of their organic counterparts and can mimic certain biological organ development processes in vitro. Therefore, they have promising applications in drug screening, disease modeling, and regenerative tissue and organ repair. The combination of bioprinting and organoids with a focus on structure and function can facilitate the further development of real organs.

Competitive landscape

Major players in the inflammatory bowel disease drug market are Corning Inc., Thermi Fisher Scientific Inc., Merck Group, Lonza Group AG, Reprocell Inc., Organovo Inc., Cellink, Aspect Biosystems, EnvisionTEC, and Cyfuse Biomedical KK. the players operating in this market have adopted various strategies including mergers and acquisitions, investments in research and development, collaborations, partnerships, regional business expansion and the launch of new drugs. For example, in October 2020, Merck partnered with D1Med, a Shanghai-based biopharmaceutical start-up, to accelerate the production of D1Med’s 3D cell culture technology applications used in the drug discovery process.

Read the full report: https://www.reportlinker.com/p06245875/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need, instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Leave a Reply

Your email address will not be published. Required fields are marked *